Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. focuses on autoimmune diseases with unmet needs and delivers therapies to help patients.

Aurinia Pharmaceuticals Inc. | 26,452 followers on LinkedIn. We pursue promising science to address some of the toughest challenges in autoimmune disease. 
 
Community guidelines:
1. By posting to our social media channels, or otherwise responding or commenting on our posts, you are agreeing to abide by these guidelines, which apply in addition to any terms and conditions or other notices or disclaimers that we may apply, or that may be applied by the host of the social media platform itself. 
 
2.

Ray Federico

CEO, BalkanTrials

Luc Opsomer, MD, MBA

VP, Associate General Counsel, Data Privacy Officer | Senior Legal Advisor| Business Partner| | DEI Leader & Champion| Life Sciences |…

Eman Ahmed-Fakhry

Sarah Beyersdorf

Today, we announced our Q3 financial results and company updates. Details can be found here: https://lnkd.in/gtp-GHXP

November is #NativeAmericanHeritageMonth , and we recognize the unique health challenges faced by Native American communities, including a higher prevalence of lupus nephritis (Lupus Foundation of America, 2023). Among Native Americans, LN occurs at twice the rate seen in other populations, highlighting the need for greater awareness and access to care. At Aurinia, we are committed to advocating for equitable healthcare and supporting efforts to improve outcomes through education, research, and community partnerships. Read more about our resources here: https://lnkd.in/gHBi5nNZ

On November 7, we will be sharing our Q3 2024 financial results and company updates. Details can be found here: https://lnkd.in/gP2wb8z3

We're excited to announce our presence at the American Society of Nephrology Conference, October 24-27, where we’ll be sharing new data demonstrating our commitment to advancing care for #lupusnephritis . Learn more: https://lnkd.in/gN5S_z_b

Hispanic women are twice as likely to develop lupus nephritis compared to white women (Lupus Foundation of America, 2023). This #HispanicHeritageMonth , we’re highlighting the need for increased awareness and support for #lupus and #lupusnephritis research among diverse populations. Learn more about our resources here: https://lnkd.in/egCmCqZM

Today, we’re excited to share that our lupus nephritis (LN) therapy has now been approved in Japan. This approval marks a significant step forward in helping even more people with LN achieve better long-term kidney outcomes. Read more: https://lnkd.in/gS4vw3en

We strongly believe our teammates who carry out our values in their everyday work are our greatest asset at Aurinia. Throughout the year, we’ll be spotlighting the winners of values-based, peer-driven ONE Aurinia Awards, celebrating the hard work and dedication of those who exemplify our four core values. Stay tuned for our upcoming winner announcements! Learn more about our mission, vision, and values: https://lnkd.in/eXGiwNDz

We’re pleased to announce our upcoming presence at the Cantor Fitzgerald Investor Conference, September 17-19. Learn more: https://lnkd.in/g3kD2wEa

Aurinia has announced Board restructuring. Details can be found here: https://lnkd.in/gq9fpUh4

Lupus nephritis disproportionately affects Hispanic women. Ahead of #HispanicHeritageMonth , we are zooming in on two impactful events to support and educate the #lupus and #lupusnephritis communities: On September 14th, CLUES is hosting the annual Fiesta Latina, a free, family-friendly community festival celebrating different aspects of Latino heritage, in St. Paul, Minnesota. We will be providing Spanish language materials for all participants. Learn more: https://lnkd.in/gNtqGVb7 On September 21st, the Lupus Society of Illinois , Northwestern Medicine and the National Kidney Foundation of Illinois are hosting an educational event on #lupusnephritis . Learn more: https://lnkd.in/gj_3_TjS Through advocacy, we’re committed to raising awareness and building a supportive network for those affected by lupus and lupus nephritis. #TogetherWeShine

Metric
Company Name	Aurinia Pharmaceuticals Inc.
Symbol	AUPH
MSH ID	COM:AURINIAPHARMA
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	CA
Stage
Employee Count	300
Website	auriniapharma.com
LinkedIn	aurinia-pharmaceuticals
Founders

Metric
Market Cap	786.60M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	175.51M
Revenue (LTM)
Revenue (NTM)
Gross Profit	161.37M
EBITDA	-71.67M
Operating Income	-83.31M
Net Income	-78.02M
EPS	-0.54
Diluted EPS	-0.54
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.92
Operating Profit Margin	-0.23
EBITDA Margin	-0.41
Net Profit Margin	-0.24
Return on Equity	-0.13
Return on Assets	-0.10
Return on Capital Employed	-0.11

COM:AURINIAPHARMA

Aurinia Pharmaceuticals Inc.

Last Close

8.77

22/11 21:00

Market Cap

786.60M

Beta: -

Volume Today

1.56M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-14.03
P/B Ratio	2.76
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.03
EV Multiple	-10.65

Metric
Days Sales Outstanding	87.19
Days Payables Outstanding	319.50
Days Inventory Outstanding	1.02K
Operating Cycle	1.07K
Cash Conversion Cycle	962.80
Asset Turnover	0.40

Metric
Operating Cash Flow	-33.46M
Free Cash Flow	-34.18M
Cash Flow to Debt	-0.01
Operating Cash Flow/Sales	-0.01
Free Cash Flow Yield	-0.03

Metric
Cash & Equivalents	48.88M
Accounts Receivable	-10.61M
Inventory	39.70M
Goodwill
Debt to Capitalization	0.21
Debt to Assets	0.17
Current Ratio	5.77
Quick Ratio	5.05

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.25
R&D to Revenue	0.31
SG&A to Revenue	1.21